Con­tin­u­ing push be­yond Covid-19 vac­cines, Mod­er­na part­ners with 'CAR-M' biotech on in vi­vo can­cer cell ther­a­pies

Since com­ing in­to a mas­sive wind­fall with its Covid-19 vac­cines, Mod­er­na has been look­ing for ways to ex­pand its mR­NA tech­nolo­gies in­to oth­er promis­ing ar­eas. On Mon­day, the biotech took its next step to­ward that goal.

Mod­er­na is part­ner­ing with Caris­ma Ther­a­peu­tics on a huge slate of “CAR-M” pro­grams to treat can­cer, the com­pa­nies an­nounced Mon­day morn­ing, promis­ing $45 mil­lion up­front and $35 mil­lion in eq­ui­ty. Though the amount of mile­stones was not spec­i­fied, the biotechs not­ed Mod­er­na has the op­tion to nom­i­nate up to 12 tar­gets for de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER